Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology

Sector: Healthcare

Phone: 403 670 7377

Fax: 403 283 0858

Website: oncolyticsbiotech.com

Address:

322 11th Avenue SW, Suite 804, Calgary, Canada

aaron03 Nov. 15 at 2:16 AM

$ONCY Has or did the meeting take place today? This is from the September 29th PR: The Company is currently scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to advance study details in regards to the First-Line pancreatic ductal adenocarcinoma trial. We'll see if we get a PR this upcoming week. This is where we'll see if Kelly is different than his predecessors. As shareholders, we want transparency.

1 · Reply

FoxM07 Nov. 14 at 11:38 PM

$ONCY enough conjecture for the week...it's falling on deaf ears.

0 · Reply

charlietwodogs Nov. 14 at 11:37 PM

$ONCY. 你满嘴狗屎 Nǐ mǎnzuǐ gǒu shǐ notable.

0 · Reply

Notable_Ex Nov. 14 at 10:54 PM

$ONCY Biotech analysts are saying "there is a lot of urgency out there" by big pharma to do deals. Mizuho's Health Care Strategist Jared Holz says thst small and midcap biotech clearly is the place to be as big pharma ramps up its deal making activities. M&A fervor and deal making urgency is expected to significantly drive small & midcap biotech acquisitions and valuations.

0 · Reply

Notable_Ex Nov. 14 at 10:15 PM

$ONCY Really? How's that Einstein?

0 · Reply

FoxM07 Nov. 14 at 9:49 PM

$ONCY the Merck news doesn't bode well for Oncy at all. Enough conjecture for the week...thx in advance. Report.

0 · Reply

Notable_Ex Nov. 14 at 9:38 PM

$ONCY Merck & Co. is spending $9.2 billion to aquire Phase 2b late-stage biotech Cidara Therapeutics and its lead influenza antiviral vaccine that was dropped by Johnson & Johnson last year. Looks as though Merck is strengthening its biologics portfolio which bodes well for other late stage I/O companies like ONCY's pelareorep, which is targeting multiple large market high value cancers, with unmet treatment needs. https://www.fiercebiotech.com/biotech/merck-co-pays-92b-owner-influenza-antiviral-janssen-rejected

0 · Reply

aaron03 Nov. 14 at 9:10 PM

$ONCY What a disappointing day! The only red stock in my portfolio. What this tells me is there's no interest in $ONCY. I hope I'm wrong. I don't want to hear an excuse about a delay in the FDA meeting. It's time for Kelly to step up.

1 · Reply

Notable_Ex Nov. 14 at 9:09 PM

$ONCY Canada's CSIS warns on China and Russia. https://www.theglobeandmail.com/politics/article-csis-china-russia-warning/

0 · Reply

Notable_Ex Nov. 14 at 9:07 PM

$ONCY https://www.msn.com/en-ca/news/canada/china-russia-spying-on-governments-businesses-in-canada-s-arctic-csis-director/ar-AA1QnU5b

0 · Reply

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 20, 2025, 9:00 AM EDT - 25 days ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Sep 29, 2025, 8:30 AM EDT - 6 weeks ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 16, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 8, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 2 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 11, 2025, 4:55 PM EDT - 3 months ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 9:05 AM EDT - 3 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 3 months ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 3 months ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 3 months ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 4 months ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 4 months ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 16, 2025, 8:30 AM EDT - 4 months ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 4 months ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 4 months ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 5 months ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 6 months ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 7:21 PM EDT - 6 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 6 months ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 6 months ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 7 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 7 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 11:11 AM EST - 9 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 7:00 AM EST - 9 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 9 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 9 months ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 9 months ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 9 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 10 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 10 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 10 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 11 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 18, 2024, 7:00 AM EST - 11 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 3, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Nov 13, 2024, 9:01 PM EST - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 11, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Aug 1, 2024, 7:55 PM EDT - 1 year ago

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

aaron03 Nov. 15 at 2:16 AM

1 · Reply

FoxM07 Nov. 14 at 11:38 PM

$ONCY enough conjecture for the week...it's falling on deaf ears.

0 · Reply

charlietwodogs Nov. 14 at 11:37 PM

$ONCY. 你满嘴狗屎 Nǐ mǎnzuǐ gǒu shǐ notable.

0 · Reply

Notable_Ex Nov. 14 at 10:54 PM

0 · Reply

Notable_Ex Nov. 14 at 10:15 PM

$ONCY Really? How's that Einstein?

0 · Reply

FoxM07 Nov. 14 at 9:49 PM

$ONCY the Merck news doesn't bode well for Oncy at all. Enough conjecture for the week...thx in advance. Report.

0 · Reply

Notable_Ex Nov. 14 at 9:38 PM

0 · Reply

aaron03 Nov. 14 at 9:10 PM

1 · Reply

Notable_Ex Nov. 14 at 9:09 PM

$ONCY Canada's CSIS warns on China and Russia. https://www.theglobeandmail.com/politics/article-csis-china-russia-warning/

0 · Reply

Notable_Ex Nov. 14 at 9:07 PM

$ONCY https://www.msn.com/en-ca/news/canada/china-russia-spying-on-governments-businesses-in-canada-s-arctic-csis-director/ar-AA1QnU5b

0 · Reply

charlietwodogs Nov. 14 at 8:10 PM

$ONCY. 你满嘴狗屎 Nǐ mǎnzuǐ gǒu shǐ notable.

0 · Reply

Notable_Ex Nov. 14 at 8:06 PM

$ONCY "China boys" here. https://www.reuters.com/world/china/white-house-says-alibaba-is-helping-chinese-military-target-us-ft-reports-2025-11-14/

0 · Reply

charlietwodogs Nov. 14 at 7:39 PM

$ONCY dead cat bounce

0 · Reply

Magnificent77 Nov. 14 at 6:31 PM

$ONCY we love some discounts

0 · Reply

exwallstcfo Nov. 14 at 5:31 PM

My top 10 holdings after this correction and going into the new year PART 2 6 $REKR 7 $SHIM 8 $GKPRF 9 $ONCY 10 $FUBO

0 · Reply

CaseyLe Nov. 14 at 3:57 PM

$ONCY I love where the direction of the FDA is going. Feels like everything is forming beautifully. Considering if we get a partnership or buyout.

1 · Reply

BuyingHighCryingLater Nov. 14 at 2:28 PM

Within the last month, $ONCY has established a Gastrointestinal Tumour Scientific Advisory Board and has reported that their anal cancer data is showing 2x the current standard of care... All eyes are on them while we wait to see what's next for them.

0 · Reply

Tunes444 Nov. 14 at 2:08 PM

$ONCY

0 · Reply

GoPatzGo123 Nov. 14 at 1:27 PM

$ONCY Indeed, the recent Q3 earnings report may not have inspired confidence among shareholders, particularly given some of the issues that appear to have been acknowledged.

1 · Reply

FoxM07 Nov. 14 at 1:00 PM

$ONCY those excerpts from the Q3 earnings report certainly aren't confidence inducing, are they? Thank heavens for the recent inundation of Oncy dispatched pumpers to tell us all is well, and a double thx to Mr Conjecture for his assurances vis à vis the accelerated approval. Maybe he should inform Jared of this certainty.

0 · Reply

GB1996 Nov. 14 at 11:58 AM

$ONCY MD&A (Sept 30, 2025) Nov 12, 2025 Financial highlights: "Oncolytics has never been profitable and expects continued substantial losses. As of Sept 30, 2025:Cash & equivalents: $12.35M.Current cash runway into March 2026. The company plans to raise capital through: - Equity issuance - Strategic collaborations - Debt arrangements No assurance additional funding will be available or on acceptable terms. Material uncertainty exists about the company’s ability to continue as a going concern."

0 · Reply

journeytc Nov. 14 at 2:14 AM

$ONCY onc should seek a second review of breast cancer result. MAHA understands how deep FDA corruption goes.

0 · Reply

Market Cap	108.39M
Revenue (ttm)	0.00
Net Income (ttm)	-23.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	850,300
Avg Vol	1,128,614
Day's Range	N/A - N/A
Shares Out	100.36M
Stochastic %K	52%
Beta	1.32
Analysts	Strong Sell
Price Target	$4.12